29. Besa E, Nowell P, Geller N, Gardner F: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 49:308, 1982.
30. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E: Danazol treatment of idiopathic myelofi-brosis with severe anemia. Haematologica 85:595-599, 2000.
31. Levy V, Bourgarit A, Delmer A, et al.: Treatment of agnogenic myeloid metaplasia with danazol—a report of four cases. Am J Hematol 53:239-241, 1996.
32. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114:78-83, 2001.
33. Canepa L, Ballerini F, Varaldo R, et al.: Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 115:313-315, 2001.
34. Elliott MA, Mesa RA, Li CY, et al.: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117:288-296, 2002.
35. Grossi A, Gavazzi S, Biscardi M, et al.: Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-Beta) and KDR expression in myeloid metaplasia with myelofibrosis. Blood 100:a4939, 2002.
36. Marchetti M, Barosi G, Balestri F, et al.: Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22:424-431, 2004.
37. Merup M, Kutti J, Birgergard G, et al.: Negligible clinical effects of thalidomide in patients with myelofibro-sis with myeloid metaplasia. Med Oncol 19:79-86, 2002.
38. Piccaluga PP, Visani G, Pileri SA, et al.: Clinical efficacy and antiangiogenic activity of thalidomide in myelofi-brosis with myeloid metaplasia. A pilot study. Leukemia 16:1609-1614, 2002.
39. Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G: Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica 86:772-773, 2001.
40. Strupp C, Germing U, Scherer A, et al.: Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 72:52-57, 2004.
41. Mesa RA, Steensma DP, Pardanani A, et al.: A phase 2 trial of combination low-dose thalidomide and pred-nisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534-2541, 2003.
42. Visani G, Mele A, Malagola M, Isidori A, Finelli C, Piccaluga P: Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs as single agents. Leukemia 17:1669, 2003.
43. Tefferi A, Elliott MA: Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 96:4007, 2002.
44. Kyrtsonis MC, Kokoris SI, Kontopidou FN, Siakantaris MP, Kittas C, Pangalis GA: Development of a myelopro-liferative disorder in a patient with monoclonal gam-mopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody. Blood 97:2527-2528, 2001.
45. Mesa RA, Elliott MA, Faoro L, Tefferi A: Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: long term outcome analysis of 2 prospective trials. Blood 102:a104, 2003.
46. Jensen M: Splenectomy in myelofibrosis. Acta Med Scand 175:533-544, 1964.
47. Hickling RA: Splenectomy in myeloid metaplasia. QJ Med 30:253, 1937.
48. Bukh H, With TK: Splenectomy in chronic non-leukemic myeloid splenomegaly with a report of osteosclerosis. Acta Chir Scand 92:507-532, 1945.
49. Green TW, Conley C, Ashburn LI, Peters HR: Splenectomy for myeloid metaplasia of the spleen. N Engl J Med 248:211-219, 1953.
50. Videbaek A: Fibrosis and sclerosis of the bone marrow. Acta Haematol 15:235-245, 1956.
51. Gomes MR, Silverstein MN, Remine WH: Splenectomy for agnogenic myeloid metaplasia. Surg Gynecol Obstet 125:106-108, 1967.
52. Schwartz SI, Bernard RP, Adams JT, Bauman AW: Splenectomy for hematologic disorders. Arch Surg 101:338-347, 1970.
53. Morgenstern L: Splenectomy for massive splenomegaly due to myeloid metaplasia. Am J Surg 122:288-293, 1971.
54. Milner GR, Geary CG, Wadsworth LD, Doss A: Erythrokinetic studies as a guide to the value of splenectomy in primary myeloid metaplasia. Br J Haematol 25:467-484, 1973.
55. Silverstein MN, Remine WH: Sex, splenectomy, and myeloid metaplasia. JAMA 227:424-426, 1974.
56. Gale D, Sacks P, Lynch S, Bothwell TH, Bezwoda W, Stevens K: The place of splenectomy in haematological disorders. S Afr Med J 48:1240-1245, 1974.
57. Mulder H, Steenbergen J, Haanen C: Clinical course and survival after elective splenectomy in 19 patients with primary myelofibrosis. Br J Haematol 35:419-427, 1977.
58. Cabot EB, Brennan MF, Rosenthal DS, Wilson RE: Splenectomy in myeloid metaplasia. Ann Surg 187:24-30, 1978.
59. Little JM: A prospective study of 100 splenectomies. AustN Z J Surg 48:390-397, 1978.
60. Silverstein MN, Remine WH: Splenectomy in myeloid metaplasia. Blood 53:515-518, 1979.
61. Benbassat J PS, Ligumski M: Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. Br J Haematol 42:207-214, 1979.
62. Jarvinen H, Kivilaakso E, Ikkala E, Vuopio P, Hastbacka J: Splenectomy for myelofibrosis. Ann Clin Res 14:66-71, 1982.
63. Coon WW, Liepman MK: Splenectomy for agnogenic myeloid metaplasia. Surg Gynecol Obstet 154:561-563, 1982.
64. Musser G, Lazar G, Hocking W, Busuttl W: Splenectomy for hematologic disease. Ann Surg 200:40-45, 1984.
65. Sharp P, Grace CS, Rozenberg MC, Ham JM: Splenectomy for massive splenomegaly. Aust N Z J Surg 55:489-492, 1985.
66. Dotevall A, Kutti J, Wadenvik H, Westin J: A retrospective analysis of a consecutive series of patients splenec-tomized for various hematologic disorders. Acta Haematol 77:38-44, 1987.
67. Benbassat J, Gilon D, Penchas S: The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol 33:128-135, 1990.
68. Brenner B, Nagler A, Tatarsky I, Hashmonai M: Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Arch Intern Med 148:2501-2505, 1988.
69. Schmitz N, Suttorp M, Schlegelberger B, Weber-Matthiesen K, Tiemann M, Sonnen R: The role of the spleen after bone marrow transplantation for primary myelofibrosis. Br J Haematol 81:616-618, 1992.
70. Barosi G, Ambrosetti A, Buratti A, et al.: Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 7:200-206, 1993.
71. Lafaye F, Rain JD, Clot P, Najean Y: Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. Nouv Rev Fr Hematol 36:359-362, 1994.
72. Jameson JS, Thomas WM, Dawson S: Splenectomy for haematologic disease. J R Coll Surg Edinb 41:307-311, 1996.
73. Mittelman MKS, Zeidman A: Splenectomy for hematologic disease—a single institution experience. Haematologica 28:185-198, 1997.
74. Bohner H, Tirier C, Rotzcher VM: Indications for and results of splenectomy in different hematologic disorders. Langenbecks Arch Chir 382:79-82, 1997.
75. Barosi G, Ambrosetti A, Centra A, et al.: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 91:3630-3636, 1998.
76. Akpek G, McAneny D, Weintraub L: Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases. J Surg Oncol 77:42-48, 2001.
77. Lofvenberg E, Wahlin A: Management of poly-cythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375-381, 1988.
78. Best PJ, Daoud MS, Pittelkow MR, Petitt RM: Hydroxyurea-induced leg ulceration in 14 patients [see comments]. Ann Intern Med 128:29-32, 1998.
79. Manoharan A, Pitney WR: Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibro-sis. Scand J Haematol 33:453-459, 1984.
80. Petti MC, Latagliata R, Spadea T, et al.: Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116:576-581, 2002.
81. Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99:352-357, 1997.
82. Mesa RA, Camoriano JK, Geyer SM, et al.: A phase 2 consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: interim analysis of 18 patients. Blood 102:a3428, 2003.
83. Giles FJ, List AF, Roboz GJ, et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral VEGF-recep-tor inhibitor, in patients with myelofibrosis with myeloid metaplasia. Blood 102:a3431, 2003.
84. Silverstein MN: Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation. Int J Radiat Oncol Biol Phys 2:1221-1222, 1977.
85. Greenberger JS, Chaffey JT, Rosenthal DS, Moloney WC: Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia. Int J Radiat Oncol Biol Phys 2:1083-1090, 1977.
86. Slanina J, Vondraczek A, Wannenmacher M: Symptomatic irradiation therapy of the spleen in advanced osteomyelosclerosis. Dtsch Med Wochenschr 111:1144-1150, 1986.
87. Wagner H Jr, McKeough PG, Desforges J, Madoc-Jones H: Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer 58:1204-1207, 1986.
88. Elliott MA, Chen MG, Silverstein MN, Tefferi A: Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505-511, 1998.
89. Bouabdallah R, Coso D, Gonzague-Casabianca L, Alzieu C, Resbeut M, Gastaut JA: Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leuk Res 24:491-495, 2000.
90. McFarland JT, Kuzma C, Millard FE, Johnstone PA: Palliative irradiation of the spleen. Am J Clin Oncol 26:178-183, 2003.
91. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG: Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 66:37-42, 2001.
92. Leinweber C, Order SE, Calkins AR: Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Cancer 68:1251-1254, 1991.
93. Koch C, Li C, Mesa R, Tefferi A: Nonhepatosplenic extrameduallry hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 78:1223-1233, 2003.
94. Steensma DP, Hook CC, Stafford SL, Tefferi A: Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 118:813-816, 2002.
95. Weinschenker P, Kutner JM, Salvajoli JV, et al.: Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am JHematol 69:277-280, 2002.
96. Battegay EJ, Raines EW, Colbert T, Ross R: TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol 154:6040-6047, 1995.
97. Rusten LS, Jacobsen SE: Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 85:989-996, 1995.
98. Dinarello CA, Cannon JG, Wolff SM, et al.: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433-1450, 1986.
99. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A: Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99:2252-2254, 2002.
100. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C: Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 85:124-127, 1991.
101. Mesa RA, Tefferi A: Survival and outcomes to therapy in leukemic transformation of myelofibrosis with myeloid metaplasia: a single institution experience with 91 patients. Blood 102:a3414, 2003.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.